(Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial

Category Primary study
JournalAnnals of Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 8bc02977d56d519d40c68c5af1918534da5b2c1e
First added on: Feb 08, 2025